Thompson Siegel & Walmsley LLC Acquires New Shares in Henry Schein, Inc. (NASDAQ:HSIC)

Thompson Siegel & Walmsley LLC bought a new position in Henry Schein, Inc. (NASDAQ:HSIC) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 728,285 shares of the company’s stock, valued at approximately $46,683,000.

Other large investors have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. lifted its holdings in shares of Henry Schein by 12.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,459 shares of the company’s stock worth $350,000 after buying an additional 606 shares in the last quarter. GHP Investment Advisors Inc. increased its holdings in Henry Schein by 5.4% during the 2nd quarter. GHP Investment Advisors Inc. now owns 54,716 shares of the company’s stock worth $3,507,000 after acquiring an additional 2,802 shares during the period. Nuance Investments LLC lifted its stake in Henry Schein by 6.2% in the 2nd quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock worth $119,440,000 after purchasing an additional 108,143 shares in the last quarter. American Century Companies Inc. boosted its holdings in Henry Schein by 3.1% in the 2nd quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock valued at $351,543,000 after purchasing an additional 162,477 shares during the period. Finally, Studio Investment Management LLC grew its position in shares of Henry Schein by 4.7% during the 2nd quarter. Studio Investment Management LLC now owns 4,502 shares of the company’s stock valued at $289,000 after purchasing an additional 204 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $70.38 on Friday. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 1.88 and a beta of 0.86. The company has a fifty day moving average of $69.21 and a 200-day moving average of $70.57. Henry Schein, Inc. has a 52-week low of $60.01 and a 52-week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.01. The business had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted $1.31 earnings per share. Equities research analysts expect that Henry Schein, Inc. will post 4.75 EPS for the current year.

Insider Buying and Selling

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Barrington Research lowered their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. UBS Group lowered their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Piper Sandler reissued an “overweight” rating and set a $86.00 price objective on shares of Henry Schein in a report on Friday, June 21st. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein has an average rating of “Hold” and an average target price of $77.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.